Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD33-AlloCART
- Development stage
- Preclinical
- Lead developer
- MaxCyte
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD33-AlloCART is an allogeneic chimeric antigen receptor (CAR) T cell therapy under development as a potential treatment for acute myeloid leukemia (AML). This therapy utilizes non-viral engineering methods, specifically MaxCyte's ExPERT™ electroporation platform, for the highly efficient delivery of biomolecules. The process involves the use of Sleeping Beauty 100X transposase mRNA and CD33-CAR transposon minicircle DNA to introduce the CAR, alongside CRISPR-Cas editing targeting the TRAC and B2M loci. This approach aims to reduce immunogenicity and manufacturing costs while preserving T cell viability and functionality, enabling the generation of functional CD33-AlloCART cells at a clinically relevant scale.
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on CD33-AlloCART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33-AlloCART.